Fabino Life Sciences SME
Listing performance
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- Listing date
- 13 Jan 2022
- Face value
- ₹10 per share
- Issue price
- ₹36 per share
- Lot size
- 3,000 shares
- Total issue size
- ₹3.24 Cr
- Market cap at offer price
- ₹7.56 Cr
- Promoter holding
- 99.43% → 56.82% pre-issue → post-issue
- ISIN
- INE0DRT01018
- Registrar
- Bigshare Services Pvt.Ltd.
- Lead managers
- Aryaman Financial Services Ltd.
- Registered office
- 105, 1st Floor, Barodia Tower, Plot No 12, D Block Central Market Prashant Vihar, New Delhi
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Market maker | 48,000 | — | — |
Application size
Minimum 3,000 shares per lot, in multiples, at ₹36
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 3,000 | ₹1,08,000 |
| S-HNI (min) | 2 | 6,000 | ₹2,16,000 |
| S-HNI (max) | 9 | 27,000 | ₹9,72,000 |
| B-HNI (min) | 10 | 30,000 | ₹10,80,000 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Valuation and performance
Valuation at offer price
| Metric | Pre-issue | Post-issue |
|---|---|---|
| Market cap | — | ₹7.56 Cr |
About Fabino Life Sciences SME
Fabino Life Sciences Limited, incorporated in 2011 and converted to public company in 2015, is engaged in manufacturing, marketing, packing, and trading of pharmaceutical, allopathic, herbal, Ayurvedic, veterinary, and wellness-focused consumer products. The company's core business involves ethical marketing of pharmaceutical formulations in the domestic market through its own distribution network and sales force under its own brand name. It manufactures Ayurvedic formulations through loan licensing facilities approved by relevant authorities, typically for periods of one to five years. The company also exports wellness and FMCG products including coffee, malt powder, protein powder, and hair shampoo. It has been awarded GMP Certification for following Good Manufacturing Practices of Ayurveda/Siddha/Unnani drugs under Schedule T of the Drugs & Cosmetics Rules, 1945 for various product categories including tablets, capsules, oils, syrups, and powders. The company emphasizes developing high-quality, affordable products for all sections of society through competent manpower and resources.
Company Analysis
from RHPFabino Life Sciences Limited manufactures and markets pharmaceutical formulations, Ayurvedic/herbal products, and wellness/FMCG items through its own distribution network in India and internationally.
Fabino Life Sciences Limited, incorporated in 2011 and converted to public company in 2015, is engaged in manufacturing, marketing, packing, and trading of pharmaceutical, allopathic, herbal, Ayurvedic, veterinary, and wellness-focused consumer products. The company's core business involves ethical marketing of pharmaceutical formulations in the domestic market through its own distribution network and sales force under its own brand name. It manufactures Ayurvedic formulations through loan licensing facilities approved by relevant authorities, typically for periods of one to five years. The company also exports wellness and FMCG products including coffee, malt powder, protein powder, and hair shampoo. It has been awarded GMP Certification for following Good Manufacturing Practices of Ayurveda/Siddha/Unnani drugs under Schedule T of the Drugs & Cosmetics Rules, 1945 for various product categories including tablets, capsules, oils, syrups, and powders. The company emphasizes developing high-quality, affordable products for all sections of society through competent manpower and resources.
Objects of the Issue
- Part Repayment of Loans ₹ 25.00 lakhs p.17
- Funding Working capital requirements ₹ 204.90 lakhs p.17
- General Corporate Purpose ₹ 50.44 lakhs p.17
- Part Repayment of Loans ₹25.00 lakhs p.61
- Funding Working capital requirements ₹204.90 lakhs p.61
- General Corporate Purpose ₹50.44 lakhs p.62
- Repayment of borrowings ₹25.00 Lakhs
- Funding capital expenditure for establishment of new product manufacturing facility ₹100.00 Lakhs
- General corporate purposes ₹199.00 Lakhs
Issue Structure
- Total Issue
- 9,00,000 Equity Shares of ₹ 10 each at ₹ 36 per share, aggregating to ₹ 324.00 lakhs
- Fresh Issue
- 9,00,000 Equity Shares of ₹ 10 each for cash at a price of ₹ 36 per share, aggregating to ₹ 324.00 lakhs
- Price Band
- ₹ 36 per share (Fixed Price Issue)
- Lot Size
- 3,000 shares and in multiples of 3,000 thereafter; subject to a minimum allotment of 3,000 shares to successful applicants
- Face Value
- ₹ 10 per share
Business Model
The company earns revenue through three primary channels: (1) Ethical marketing of pharmaceutical formulations sold domestically through its own distribution network of approximately 75 distributors/stockists/super stockists; (2) Manufacturing and marketing of Ayurvedic, herbal, cosmeceutical, wellness and food supplement products, some manufactured in-house and some through loan licensing arrangements; (3) Trading and exporting wellness and FMCG products like coffee, malt powder, protein powder, and hair shampoo. The company does not own its own manufacturing facility for allopathic pharma goods and relies on third parties for sourcing these products for resale.
Business Segments
SWOT Analysis
- • Diversified product portfolio in pharmaceutical, herbal, and wellness sectors(p.17)
- • GMP Certification for Ayurveda manufacturing standards(p.17)
- • Established distribution network across India(p.25)
- • Loan licensing arrangement for Ayurvedic formulations(p.17)
- • Experienced promoter with 17+ years in pharmaceuticals(p.79)
- • Diverse product portfolio across multiple segments(p.79)
- • Well-established brand with extensive trademark registrations(p.80)
- • Low leverage balance sheet with no bank debt(p.80)
- • Significant revenue concentration among few customers(p.21)
- • Dependence on few raw material suppliers(p.26)
- • No ownership of manufacturing and office facilities(p.22)
- • Unsecured loans from promoter and directors callable at any time(p.23)
- • Low profit margins compared to industry standards(p.24)
- • Negative operating cash flows in recent periods(p.24)
- • No ownership of manufacturing facilities for Allopathic pharma products(p.24)
- • Unregistered trademarks vulnerable to infringement(p.29)
- • High dependence on top customers(p.96)
- • Limited human resources capacity(p.96)
- • Low manufacturing capacity utilization(p.96)
- • Significant revenue decline from prior year(p.78)
- • Growth in Indian pharmaceutical market driven by rising medicine spending(p.17)
- • India's position as global pharmaceutical leader and vaccine supplier(p.17)
- • Strategic use of IPO proceeds for working capital expansion(p.17)
- • Loan repayment from IPO proceeds to improve financial ratios(p.23)
- • Expansion into new geographic markets and product lines(p.17)
- • Working capital augmentation to expand order-taking capacity(p.80)
- • Geographical expansion into new markets(p.81)
- • Growing pharmaceutical market in India(p.75)
- • Digital marketing and e-commerce expansion(p.81)
- • Intense competition in pharmaceutical and herbal medicine sectors(p.25)
- • COVID-19 pandemic continued uncertainty and impact(p.23)
- • Regulatory changes in pharmaceutical and drug sector(p.35)
- • Macroeconomic uncertainties affecting Indian economy(p.36)
- • Inflation impacting cost structure and pricing ability(p.37)
- • Foreign investment restrictions limiting capital attraction(p.34)
- • Reliance on distributors outside company control(p.23)
- • Terrorist attacks and civil unrest in India(p.35)
- • Intense fragmented industry competition(p.99)
- • Price competition as primary market decision factor(p.99)
- • No entry barriers in pharmaceutical manufacturing(p.99)
- • Regulatory dependence on licensing and government approvals(p.77)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Atul Kumar Jain | Promoter | 91.67% | 52.38% |
| Vandana Jain | Promoter Group | 7.00% | 4.00% |
| Shreya Jain | Promoter Group | 0.33% | 0.19% |
| Kamal Jain | Promoter Group | 0.23% | 0.13% |
| Shanta Jain | Promoter Group | 0.20% | 0.11% |
| Atul Kumar Jain | Promoter/Chairperson and Managing Director | 91.67% | 52.38% |
| Vandana Jain | Promoter Group | 7.00% | 4.00% |
| Shreya Jain | Promoter Group | 0.33% | 0.19% |
| Kamal Jain | Promoter Group | 0.23% | 0.13% |
| Shanta Jain | Promoter Group | 0.20% | 0.11% |
| Atul Kumar Jain | Promoter | 91.67% | — |
Leadership
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.